GLP-1 receptor agonist monotherapy appears largely bone-neutral, but dual agonists — such as tirzepatide targeting both GLP-1 and GIP receptors — may carry elevated osteoporosis and fracture risk. The mechanism appears indirect: greater magnitude of weight loss and concomitant lean body mass reduction, rather than direct osteotoxicity, drive osteoclastic activity. High-risk phenotypes include postmenopausal women, older adults with low baseline bone mineral density, and patients on concurrent bone-active agents. The authors propose urine deoxypyridinoline (DPD), a bone-specific collagen crosslink released during osteoclastic resorption, as a dynamic, radiation-free alternative to serial DXA scanning for early detection of skeletal disturbance.
This perspective arrives at a critical moment. GLP-1RA prescriptions have surged globally, yet bone health monitoring protocols remain absent from most clinical guidelines. DPD is not a new biomarker — it has been used in osteoporosis research for decades — but its application as a routine surveillance tool within GLP-1RA treatment frameworks is genuinely underexplored. The argument is clinically logical: DPD responds faster than DXA to remodeling changes, requires no radiation, and could trigger therapeutic adjustment before structural damage accumulates. However, this is a narrative commentary, not a clinical trial, so causal directionality and optimal DPD thresholds remain unestablished. The incremental value of DPD over other resorption markers like CTX also needs head-to-head validation. Considered promising but hypothesis-generating — prospective cohort data are urgently needed.